N. K. Altorki

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment

This study shows that tumor organoids with mutant p53 are more sensitive to the combination of PARP inhibitor and temozolomide than those with wild-type p53.

Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells.

The paper uses proximity proteome mapping to show that anti-PD-L1 therapy disrupts specific PD-L1-dependent pathways in EGFR-mutant lung cancer cells, leading to altered cell migration and EGFR stability.

Evolution of immune escape mechanisms in the progression from preinvasive to invasive human lung adenocarcinoma.

This study compares the immune microenvironment of preinvasive and invasive lung adenocarcinoma using multiplex immunofluorescence, finding increasing immunosuppression with disease progression.